Follow The Filings

PYXS Pyxis Oncology Inc.

Health Care, filed as PYXIS ONCOLOGY INC (COMMON STOCK), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 1 Owner
  • Max 0.4%
  • $2.6M
  • 1 reduce

In 2026 Q2 Palo Alto Investors trimmed Pyxis Oncology.

Who owns this now

Largest portfolio weights among holders, up to 0.4% (Palo Alto Investors). Not free-float ownership.

  1. Palo Alto Investors Reduce 0.36%

Who owns PYXS

Sorted by value, long equity only, as of 2026 Q2.

History
Palo Alto Investors 0.36% Reduce −14.5% 864,277 $2.6M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by PYXS's executives, directors and 10% owners in the last 12 months, from their Form 4s

All PYXS insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $107K sold by 1 insider under 10b5-1 plans
  1. GordonMD Global Investments LP 10% owner, +3 joint filers
    Buy
    — 5,517,000 shares +55% to stake
    Traded Oct 1 Filed Oct 2
    ↗
  2. Jakob Dupont Director
    Planned sale
    $107K 35,000 shares at $3.06 48% of stake
    Traded Jun 30 Filed Jul 2
    ↗
  3. Rachel Humphrey Director
    Planned sale
    $16K 15,496 shares at $1.03 16% of stake
    Traded Apr 14–21 Filed Mar 25
    ↗

Also filed in the last 12 months, not counted as buying or selling: 1 stock grant and 1 option exercise.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
DEF 14A Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 1.01,8.01,9.01 Filing Doc
424B5 FORM 424B5 Filing Doc
424B5 FORM 424B5 Filing Doc
424B5 FORM 424B5 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
424B2 Filing Doc
8-K 2.02 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 1.01,3.02,7.01 Filing Doc
8-K 5.07 Filing Doc
8-K 2.02 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
8-K/A 5.02 Filing Doc
DEFA14A Filing Doc
8-K 2.02,7.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 1 day ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue — $16.15M $13.86M
Gross profit * — $15.67M $11.47M
Gross margin * — 97.1% 82.8%
Net income -$73.79M -$77.33M -$79.62M
Net margin * — -478.9% -574.5%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $124.6M $132.44M $72.1M
Total non-current assets * $49.12M $24.74M $19.42M
Total assets $173.73M $157.18M $91.52M
Total current liabilities $25.76M $17.68M $21.13M
Total non-current liabilities * $22.26M $18.75M $16.98M
Total equity $125.7M $120.75M $53.41M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$70.71M -$57.67M -$63.5M
Cash from investing -$104.85M $8.16M $58.86M
Cash from financing $5.93M $59.33M $0.594M
Net change in cash -$169.63M $9.81M -$4.05M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.